Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers

Cancer Letters

Volumn 247, Issue 1-2, 2007, Pages 98-102

  Sakaguchi, Hideki ^a   Fujimoto, Jiro ^a   Hong, Bao Li ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lymph node metastasis; Osteopontin; Prognosis; Uterine cervical cancer

Indexed keywords

GLYCOPROTEIN; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CLINICAL ARTICLE; CYTOPLASM; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; SURVIVAL RATE; UTERINE CERVIX CANCER;

ADULT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; OSTEOPONTIN; PROGNOSIS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 33845643114     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.03.026     Document Type: Article

References (33)

1. Senger D.R., Wirth D.F., and Hynes R.O. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16 (1979) 885-893
2. Craig A.M., and Denhardt D.T. The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 100 (1991) 163-171
3. Denhardt D.T., and Guo X. Osteopontin: a protein with diverse functions. Fed. Am. Soc. Exp. Biol. J. 7 (1993) 1475-1482
4. Denhardt D.T., and Noda M. Osteopontin expression and function: role in bone remodeling. J. Cell. Biochem. Suppl. 30-31 (1998) 92-102
5. O'Regan A., and Berman J.S. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 81 (2000) 373-390
6. Weber G.F. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 1552 (2001) 61-85
7. Hijiya N., Setoguchi M., Matsuura K., Higuchi Y., Akizuki S., and Yamamoto S. Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J. 303 (1994) 255-262
8. Tuck A.B., O'Malley F.P., Singhal H., Tonkin K.S., Harris J.F., Bautista D., et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med. 121 (1997) 578-584
9. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 79 (1998) 502-508
10. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18 (1999) 4237-4246
11. Rudland P.S., Platt-Higgins A., El-Tanani M., De Silva Rudland S., Barraclough R., Winstanley J.H., et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 62 (2002) 3417-3427
12. Shijubo N., Uede T., Kon S., Maeda M., Segawa T., Imada A., et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 160 (1999) 1269-1273
13. Chambers A.F., Wilson S.M., Kerkvliet N., O'Malley F.P., Harris J.F., and Casson A.G. Osteopontin expression in lung cancer. Lung Cancer 15 (1996) 311-323
14. Schneider S., Yochim J., Brabender J., Uchida K., Danenberg K.D., Metzger R., et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin. Cancer Res. 10 (2004) 1588-1596
15. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., et al. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 5 (1999) 2271-2277
16. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst. 94 (2002) 513-521
17. FIGO news. Int. J. Gynecol. Obstet. 28 (1989) 189-193
18. McCarty Jr. K.S., Miller L.S., Cox E.B., Konrath J., and McCarty K.S. Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109 (1985) 716-721
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
20. Gotoh M., Notoya K., Ienaga Y., Kawase M., Makino H., Sakamoto M., et al. Enhancement of osteogenesis in vitro by a novel osteoblast differentiation-promoting compound, TAK-778, partly through the expression of Msx2 overexpression of osteopontin in hepatocellular carcinoma. Eur. J. Pharmacol. 451 (2002) 19-25
21. Pan H.W., Ou Y.H., Peng S.Y., Liu S.H., Lai P.L., Lee P.H., et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98 (2003) 119-127
22. Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer 79 (1998) 127-132
23. Schorge J.O., Drake R.D., Lee H., Skates S.J., Rajanbabu R., Miller D.S., et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin. Cancer Res. 10 (2004) 3474-3478
24. Brakora K.A., Lee H., Yusuf R., Sullivan L., Harris A., Colella T., et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol. Oncol. 93 (2004) 361-365
25. Tuck A.B., Elliott B.E., Hota C., Tremblay E., and Chambers A.F. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell. Biochem. 78 (2000) 465-475
26. Yoneda T., Williams P.J., and Niewolna M. Promotion of angiogenesis and enhancement of breast cancer metastasis to bone. Bone 23 (1998) 201
27. Wu Y., Denhardt D.T., and Rittling S.R. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br. J. Cancer 83 (2000) 156-163
28. Oates A.J., Barraclough R., and Rudland P.S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13 (1996) 97-104
29. Adwan H., Bauerle T.J., and Berger M.R. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 11 (2004) 109-120
30. Behrend E.I., Craig A.M., Wilson S.M., Denhardt D.T., and Chambers A.F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 54 (1994) 832-837
31. Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., and Tamaya T. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers. Br. J. Cancer 79 (1999) 1249-1254
32. Fujimoto J., Sakaguchi H., Hirose R., Wen H., and Tamaya T. Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers. Cancer Res. 59 (1999) 3041-3044
33. Fujimoto J., Sakaguchi H., Aoki I., and Tamaya T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 60 (2000) 2632-2635